The development of APS-related PE is driven by the pathogenic activity of antiphospholipid antibodies, particularly anti-β2-glycoprotein I (anti-β2-GPI) antibodies, which play a central role in initiating thrombotic processes through endothelial activation and dysfunction [3,4,5]. This evidence concerns the gene APOH and autoimmune polyendocrinopathy.